As communicated through a press release on March 11, 2025, the board of directors of PEPTONIC Medical AB (publ) (the “Company”) decided to submit an
As part of its growth strategy in the US market, Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has established a new wholly-owned subsidiary, Peptonic
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the press release issued on March 14, 2025, titled “Court of Appeal convicts former employees
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Court of Appeal has overturned the District Court’s acquittal in the insider trading case
Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) announces that the Uppsala District Court has approved the Company’s application for corporate restructuring. This decision enables
The Board of Directors of Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) has today decided to submit an application for corporate restructuring. This decision
